Ifwe were as effective in treating cancer as we are in treating most bacterial diseases, it probably would not be necessary to discuss the philosophy and methodology of clinical cancer research. Unfortunately, however, cancer treatment often cannot be characterized as effective. Furthermore, the prevailing methodology in clinical cancer research, i.e. randomized controlled trials, is not productive. The breakthroughs that have been achieved in cancer treatment during the last three decades have not resulted from randomized controlled trials1,2 ( Table  1 ).It would appear that cancer treatment has reached a plateau and the time is now ripe to re-evaluate strategies in clinical cancer research. Looking first at the past 3 -S , how has progress been achieved in medicine during its long historical development? Historical perspective During the prehistoric period, attempts by primitive man to cure diseases and relieve suffering were based on instinct and experience. Serious and disabling diseases, however, were considered of supernatural origin. Early Greek philosophers in the period 600-400 DC were the first to refuse to be guided solely by supernatural influences and tried to explain the world with logic. Hippocrates, born in 460 DC, applied the power of observation and logical reasoning, viewed diseases with the eye of a naturalist, studied the patient in his environment and developed a rigid method of medical examination. He was followed by Aristoteles (384-322 BC), the first great biologist, whose theories on teleologism and rationalism completed the formulation of Hippocratian medicine and profoundly influenced the development of medicine.
Even after Aristoteles and the decline of classical culture in Greece, Greeks remained the leading authorities in medicine for centuries. The dominant figure in the period of the Roman Empire was Galen (AD 130-200), a Greek practising in Rome. He followed the Hippocratic method of observation and, in addition to making innovations in almost every branch of medicine, he designed the first experimental methods and formulated medicine into a com-plete scientific system. Galen profoundly influenced medicine, but Aristotelian and his own dogmatisms hindered the progress of medical thought for centuries. The founder of modern anatomy, Vesal, was the first revolutionist who dared to challenge Galen's authority and his anatomical descriptions. He was followed, during the Renaissance, by Francis Bacon, whose theories on scientific empiricism dominated the thought of scientists, and prepared the rise of scientific medicine in the 19th century. Descartes, at approximately the same time as Bacon, developed the concept of Cartesian dualism -the separation of body and mind -believing that his theory would result in removing from medicine all ethico-religious taboos and thus contribute to the advancement of science and medicine. For the last three hundred years Cartesian dualism has prevailed in the scientific and philosophical view of the human body which is often conceived 'as a purely passive machine driven by mechanical causality". Scientific determinism, Indeterminism Claude Bernard, the leading physiologist in France, developed the theory of scientific determinism and pointed out the difference between the 'observing' and 'experimental' physician7. Experiments in Claude Bernard's laboratory were always carefully planned and this was, for that period, a major methodological contribution. Bernard's determinism, as a philosophical system, dominated applied science and medicine in the 19th and the beginning of the 20th century. Today, however, we no longer talk about 100% or 0% associations. We live in a period of statistical associations, of indeterminism, in all sciences, from microscopic physics to biology. We also live in an era of scientific and technological revolution, with electronics, computers, cybernetics and spectacular advances in science and molecular biology.
The technological revolution, the scientific advances, and the establishment of indeterminism in the sciences on which medicine is now based, have also created a style of clinical investigation which seems altogether different from what it was", The Hippocratic principle of exclusive commitment to patients' welfare, implying totally individualized care, is frustrated and, in randomized controlled trials, violated. The systematic manipulation of subjects in modern clinical investigation causes a conflict between the role of the doctor as physicianhealer with his commitment exclusively to the patient, and his role as the physician-investigator with his commitment to the promotion of science. Modern clinical investigation indeed generates some of the most difficult and perplexing moral problems",
Randomized clinical trials
Clinical trials are widely regarded as the principal method of obtaining a reliable evaluation of treatment effect on patients", The term means any form of planned experiment which involves patients and is designed to elucidate the most appropriate treatment for future patients with a given condition. The essential characteristic of a clinical trial is that the results from a limited sample of patients are used to make inferences about how treatment should be conducted in the general population of patients who will require treatment in the future". The sample used, therefore, must be representative of the whole, i.e. of the general population of patients.
Conversely, the study oftreatment of an individual case is not considered a clinical trial because there are many biological variations, the diseases and the patients not being at all homogeneous; it is thus impossible to make a valid generalization from one case. In a clinical trial, however, if the number of patients in the study and the control group is sufficiently large, our conclusions could be reliable!". The question posed so often is how many patients are really sufficient in order to have a representative sample?
Clinical trials are classified by the type of primary treatment, i.e. chemotherapy, surgery and/or radiotherapy, or other types of treatment or other forms of medical management. Drug trials are usually divided into four phases of experimentation, but phase III is considered to be the most important. In this phase 'standard' treatment is usually compared with the new drug which was shown 'to be reasonably effective' in the previous phases. This phase involves a substantial number of patients and is considered to be the most rigorous and extensive type of scientific clinical measurement of the effectiveness of a new treatment. To some people the term 'clinical trial' is synonymous with a full-scale phase III, which is considered the 'gold standard' of any modem clinical research.
Shortcomings
During the last 30 years randomized controlled trials have been widely applied to every type of cancer therapeutic problem. Gradually, the original methodology was significantly improved by new techniques such as stratification, unbalanced randomization, pre-randomization, adjustment, modelling, and other modifications 2 • JJ • 12 • Yet this methodology still has serious limitations and several controversies remain. Gehan, Freireich et al. and several others 2 • JJ • 1 3 -16 have stressed the shortcomings and the difficulties with this controlled trial methodology ( Table 2 ). The use of a concurrent control group, according to the Freireich group, does not verify differences in the passage of time, for it is not known if the differences between the two groups are valid for selection of therapy in the future, because the continuation in the future of the found differences is not proven. Therefore, 'historical controls' are not considered to be useless 2 • 1 1 • Objections, however, are made on the basis that historical controls are not usually comparable, because there are always differences (1) in the selection of patients and (2) in the experimental environment.
Another limitation inherent in controlled trials is that we compare two or three therapeutic methods in order to define which one is better, but many other Definition offalse positive and false negative differences Identification of subgroups of patients who benefit from the new treatment therapeutic methods usually exist and the question of how to rank this 'better method' among the many other types of therapy that exist is left unanswered. According to Freireich and colleagues, it is more important to measure the new treatment 'objectively and quantitatively' and also 'in the dimension of time'.
False positives. False negatives
Also controversial and arbitrary is the mode of defining false positive and false negative differences in the controlled trials. For false positives, the differences are usually set at the 5% level (P < 0.05)which means that the probability that the proposed treatment is not really effective is less than 5%. For false negatives, however, the level is usually 0.8 which means that we accept a 20% probability that our results are false negative. Both 5% and 20% are arbitrary. They more or less depend on the investigators and on the therapy under evaluation.
Who will benefit?
The most difficult, but perhaps the most important, issue is to establish which subgroup or subgroups of patients will really benefit from the new treatment. As pointed out earlier, the biological variations in patients and in the specific disease are considerable and there are many factors which influence the response to a specific treatment. For example, in cancer of the breast we can define today probably more than 35 groups and subgroups, each with a different prognosis and a different probability of response to therapy (Table 3) .
Freireich suggests that, in order to extrapolate the results of a study to groups and subgroups of patients, we must find a way to evaluate the different variables. He proposes the use of multivariate statistical analysis, 'stepwise forward logistic regression analysis', as a method for evaluating the degree of associations of the different variables. The problem is that we need a large number of patients -probably more than 200-in order to estimate for each variable the degree of association with prognosis and response to therapy.
The new methodology of controlled trials has unquestionably made certain significant contributions, but it is far from perfect and its applications are limited. Furthermore, there is a clear probability that it can hinder the discovery of new and more effective therapies. Table 3 . Cancer of the breast: some factors contributing to the prediction of response to a given treatment Age ofthe patient Hormonal status of the patient Size of the primary tumour Hormonal receptors Regional lymph node involvement Time interval between symptomatic onset and diagnosis Number of patients. The patient as a numbered individual As already mentioned, the biological variations are so numerous and the patient groups and subgroups so many, that in controlled trials we need a great number of patients in order to reach a reasonable conclusion -and this is seldom achieved. Of course, it can be argued that we expect only a limited increase of our knowledge with these trials -but the point is not there. Whatever breakthroughs have been achieved in clinical cancer medicine, they have not resulted from controlled trials. The intellectual effort, manpower, time, and money spent in these trials has to be calculated and evaluated in light of this low productivity. Are these extensive and expensive trials really worthwhile?
At the same time there are several important ethical and philosophical problems involvedv" which need to be discussed. One of the main ethical issues is informed consent. To what extent can patients really grasp their condition and therefore sign a meaningful consentf'" And if they do sign, to what extent does this awareness lead to severe emotional distress? Are the ramifications of informed consent the same for a patient with early cancer of the breast and one with advanced malignant melanoma? Other questions involve the physicianpatient relationship in a randomized trial 1 7 -19. Patients in a randomized trial are reduced to numbers and this has a dehumanizing effect. Actually the patient's fate is almost decided by the toss of a coin. It is significant that patients believe that consent forms are meant to 'protect the physician's right'!", and this certainly does not promote the 'trust' on which the patient-physician relationship is usually based. Disease after all essentially means a loss of certain specific freedoms and this definition certainly holds true for cancer patients. How do randomized trials affect these patients who have lost so much of their freedom and have become so dependent?
Are not the randomized trials in fact the most glaring expression of a return to Cartesian dualismthe separation of body and mind? The modern philosophical approach perceives the human body not just as a causal mechanism but essentially as an 'intentional' entity always goal-oriented". This philosophical view conflicts with the rationalization approach of controlled trials. We must, however, accept that randomized trials mean certain, though limited, progress and that proper informed consent means that our patients'rights and humanity must be safeguarded. Randomized trials and informed consent are both here to stay but, I believe, in a drastically modified form. A balance must be found in which human values are respected while the continuous advancement of medicine is assured. The philosophy of the applicability of randomized trials should differ between early stage cancer and in the hopeless, very advanced stages. The same consideration applies to informed consent.
Conclusions
It is often charged that medicine today is becoming less humane and that we are applying scientiflc and technological advances that lose sight of human values. It is also said that modern medicine is directionless. These are real questions, particularly in clinical cancer research. Do we need today a new medical philosophy in the practice of medicine? Is the teleological definition of medicine as 'a human activity concerned with the reconstitution and maintenance of health', still true? Is Cartesian medicine, and the reduction of the human body to a physiological machine, obsolete and dehumanizing? Do we still study human nature in the same manner as we do the natural world and is this not an obsolete approach? The search for answers to these serious questions and the search for the meaning of modern medicine can probably be attempted through a new philosophy adjusted to the rapid advances and changes of modern human societies. Any medical philosophy, however, should never conflict with the eternal meaning of medicine, old or new, i.e. that medicine is basically a moral enterprise.
